General Cancer
Moving Beyond BCG in Bladder Cancer
Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies is relevant.
Read More
Roundtable Roundup: Bladder Cancer
In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.
Avelumab Maintenance Therapy Enhances Survival in Advanced Urothelial Cancer
Avelumab plus best supportive care improved survival vs best supportive care alone in advanced urothelial carcinoma, regardless of diabetes status.
Enfortumab Vedotin Improves Outcomes in Advanced Urothelial Cancer
Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial.
Enfortumab Vedotin Combo Doubles PFS vs Chemo in Urothelial Cancer
Enfortumab vedotin plus pembrolizumab doubled progression-free survival vs chemotherapy in urothelial cancer.
Datopotamab Deruxtecan Shows Promise in Advanced Urothelial Cancer
Datopotamab deruxtecan showed promising activity in advanced urothelial cancer in a phase 1 study.